JPRN-jRCTs061180075已完成2 期
Open-label Phase II Study of Everolimus Plus Endocrine Therapy in Postmenopausal Women with ER+, HER2- Metastatic Breast Cancer. - Chloe trial
Shien Tadahiko0 个研究点目标入组 44 人开始时间: 2019年3月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
These results indicated the additinal effect of mTOR inhibitor to AI, even if the tumor has sensitivity to AI monotherapy.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •1, Patients who are histologically diagnosed as having breast cancer.
- •2, The cancer is immunohistochemically ER-positive (>10%) and HER2- negative (0/1+) (or HER2-negative based on ISH testing).
- •3, Patients who have one or more measurable lesions according to RECIST (Ver. 1.1).
- •As for bone lesions, patients who have measurable osteolytic or osteolytic osteoblastic lesions by CT or MRI (> 1cm in length) are eligible.
- •4, Patients with metastatic breast cancer that satisfy one of following two conditions:
- •1) Patients with remote metastasis judged not to be indicated for surgical resection at the first visit.
- •2) Patients with metastatic breast cancer except for local recurrence (the term local here refers to the chest wall surrounded by the following areas: upward to subclavian margin, downward to costal arch, inward to medial sternal margin and outward to the frontal margin of latissimus dorsi muscle). Patients with local recurrence which is not indicated for surgical resection due to diffuse lesions are eligible.
- •5, If patients received post-operative endocrine therapy, a 12 month or longer period must have passed since the end of the last administration. History of post-operative chemotherapy and elapsed time from chemotherapy, as well as the regimen of post-operative endocrine therapy, do not matter.
- •6, Among patients who start the treatment with an AI agent within 5-7 months previously. Patients who have not received chemotherapy or received just 1 regimen of chemotherapy.
- •7, Patients who have no history of treatment with everolimus.
- •8, Patients who are post-menopausal women.
- •9, Patients with ECOG performance status (PS) of 0 or 1. Patients with PS2 due to bone metastasis is allowed.
- •10, If patients have received radiation therapy, a 14 day or longer period must have passed since the end of the last radiation session.
- •11, Adequate organ functions.
- •12, Written informed consent.
排除标准
- •1, Patients who have active double cancer (simultaneous double cancer or metachronous double cancer within 5 years of disease-free period). Carcinoma in situ (intraepithelial carcinoma and mucosal carcinoma) that is judged to be already cured will not be classified as active double cancer
- •2, Patients who have a history of serious drug hypersensitivity.
- •3, Patients who have serious concomitant diseases (including pulmonary fibrosis or interstitial pneumonia, uncontrollable diabetes, serious cardiac dysfunction, renal failure, hepatic insufficiency, cerebrovascular disease and ulcer(s) requiring a blood transfusion).
- •4, Patients who have an active infectious disease requiring systemic treatment.
- •*Patients who are HBs antigen positive and HBc antibody positive, and/or HBs antibody positive.
- •*Patients who are infected with HCV or have a history of HCV infection.
- •5, Patients who have active hemorrhagic diathesis or who are being treated with an oral vitamin K antagonist
- •6, Patients with cerebral metastasis that is symptomatic or requires treatment.
- •7, Patients who have been administered medicines known as potent CYP3A inhibitors or CYP3A inducers (rifabutin, rifampicin, clarithromycin, ketoconazole, itraconazole, voriconazole, ritonavir, or telithromycin).
- •8, Patients who have been treated with hormone replacement therapy.
- •9, Patients who have a mental disorder that affects the informed consent process.
- •10, Patients who are judged to be inappropriate to participate in this study on the basis of physician's assessment.
研究者
相似试验
终止
2 期
Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers SyndromePeutz-Jeghers SyndromeNCT00811590University of Utah3
已完成
2 期
Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NETGastrointestinal NeoplasmsNCT01567488Grupo Espanol de Tumores Neuroendocrinos43
已完成
2 期
SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath TumorsMalignant Peripheral Nerve Sheath TumorsSarcomaMPNSTNCT01661283Sarcoma Alliance for Research through Collaboration25
已完成
2 期
S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By SurgeryMalignant MesotheliomaNCT00770120SWOG Cancer Research Network61
终止
2 期
Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line ChemotherapyLymphomaNCT00727207Technical University of Munich35